Shopping Cart
- Remove All
- Your shopping cart is currently empty
A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
2 mg | $43 | In Stock | |
5 mg | $68 | In Stock | |
10 mg | $92 | In Stock | |
25 mg | $219 | In Stock | |
50 mg | $378 | In Stock | |
100 mg | $558 | In Stock | |
1 mL x 10 mM (in DMSO) | $75 | In Stock |
Description | A-366 is a highly selective peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP, respectively.It is more than 1,000-fold selective for G9a and GLP over the other 21 methyltransferases. It is an inhibitor of the Spindlin1-H3K4me3 interaction with an IC50 of 182.6 nM.It exhibits high affinity for human H3R with a Ki value of 17 nM, and shows subtype selectivity between subgroups of the histaminergic and dopaminergic receptor families. |
Targets&IC50 | G9a/GLP:3.3 nM |
In vitro | For tumor cell growth, A-366 had less toxic effects than some other G9a/GLP small molecule compound inhibitors, and no difference in the methylation effect on H3K9me2. Various leukemia cell lines were treated with A-366 in vitro, and these tumor cells would produce significant differentiation and morphological changes. |
In vivo | For tumor cell growth, A-366 had less toxic effects than some other G9a/GLP small molecule compound inhibitors, and no difference in the methylation effect on H3K9me2. Various leukemia cell lines were treated with A-366 in vitro, and these tumor cells would produce significant differentiation and morphological changes. |
Kinase Assay | 7.5× compounds are added to a 96-well PolyPlate containing 60 μL of Buffer per well with substrates CoA (200 μM), ATP (400 μM), and [14C]citrate. Reaction is started with 4 μL (300 ng/well) ACL, and the plate is incubated at 37°C for 3 h. Th |
Cell Research | PC-3 prostate adenocarcinoma cells are incubated in triplicate with DMSO or the indicated concentrations of A-366 or UNC0638 for 72 hours. H3K9me2 levels are assessed by In-Cell Western assay. (Only for Reference) |
Alias | A366, A 366 |
Molecular Weight | 329.44 |
Formula | C19H27N3O2 |
Cas No. | 1527503-11-2 |
Smiles | COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |
Relative Density. | 1.29 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | 1eq. HCl: 32.9 mg/mL (100 mM) DMSO: 32.9 mg/mL (100 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
1eq. HCl/DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.